A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Cited by (625)

Items 401–500 of 625

1. Cushing’s Syndrome
   Krystallenia Alexandraki, Ashley Barry Grossman · 2013 · Springer eBooks
2. Physiological and Pathophysiological Alterations of the Neuroendocrine Components of the Reproductive Axis
   Ralf M. Nass, Kristin D. Helm, William S. Evans · 2013 · Elsevier eBooks
3. Effectiveness of low‐dose pasireotide in a patient with Cushing's disease: antiproliferative effect and predictivity of a short pasireotide suppression test
   Erika Maria Grossrubatscher, Benedetta Zampetti, Paolo Dalino Ciaramella, Paola Doneda, Paola Loli · 2015 · Clinical Case Reports
4. Cushing Disease: Diagnosis and Treatment
   Christina Tatsi, Constantine A. Stratakis · 2019 · Contemporary Endocrinology
5. Endocrine Disorders that Cause Diabetes
   Rachel E. Jennings, Neil A. Hanley · 2016 · Wiley eBooks
6. Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE)
   Giovanna Muscogiuri, Manuela Albertelli, Giorgio Arnaldi, Luigi Barrea, Giuseppe Bellastella, Marco Bonomi, Marina Caputo, Massimiliano Caprio, Angelo Cignarelli, Ludovico Di Gioia et al. · 2026 · Journal of Endocrinological Investigation
7. Therapeutic innovations in endocrine diseases - Part 4 : Pasireotide: Long-acting release somatostatin analogue.
   J. Wemeau · 2016 · Presse medicale
8. The Effect of Pituitary Gland Disorders on Glucose Metabolism: From Pathophysiology to Management
   Guy I. Sydney, Konstantinos G. Michalakis, Ilias P. Nikas, Eleftherios D Spartalis, Stavroula Α. Paschou · 2020 · Hormone and Metabolic Research
9. New Approaches to the Treatment of Hypercortisolism
   Riccardo Pofi, Dario De Alcubierre, Jiawen Dong, Jeremy Tomlinson · 2024 · Annual Review of Medicine
10. Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
    Rossella Mazzilli, Virginia Zamponi, Camilla Mancini, Beatrice Giorgini, Bianca Golisano, Nevena Mikovic, Giulia Pecora, Flaminia Russo, Maurizio Martiradonna, Piero Paravani et al. · 2025 · Endocrine
11. Efficacy and safety of pasireotide in patients with Cushing’s disease: a monocentric experience
    Ylenia Alessi, Angela Alibrandi, Filippo Flavio Angileri, Francesco Ferraù, Salvatore Cannavò · 2025 · Endocrine
12. New options in the treatment of Cushing’s disease: a focus on pasireotide
    Nicolas Chevalier, Poullot · 2013 · Research and Reports in Endocrine Disorders
13. Metyrapone for Long-Term Medical Management of Cushing’s Syndrome
    Andrea N. Traina, Ashley Farr, Ritu Malik, Robert James Bingham · 2013 · Case Reports in Endocrinology
14. Utility of Exposure‐Response Analysis in Regulatory Decision on the Selection of Starting Dose of Pasireotide for Cushing Disease
    Jingyu Yu, Sang Seop Chung, Immo Zadezensky, Ke Hu, Christelle Darstein, Jerry R. Nedelman, Nitin Mehrotra · 2015 · The Journal of Clinical Pharmacology
15. Adrenal Pathologies During Pregnancy and Postpartum
    Matthieu St‐Jean, Isabelle Bourdeau, André Lacroix · 2019 · Elsevier eBooks
16. Innovative tumour targeting therapeutics in Cushing's disease
    Vivian von Selzam, Marily Theodoropoulou · 2022 · Best Practice & Research Clinical Endocrinology & Metabolism
17. Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas
    Elena Sabini, Amna Nabeel Khan, Patrizio Caturegli · 2023 · Endocrine Related Cancer
18. Case report: Complete restoration of the HPA axis function in Cushing’s disease with drug treatment
    Joanne Thanh-Tâm Nguyen, Amandine Ferrière, Antoine Tabarin · 2024 · Frontiers in Endocrinology
19. SOM230: A New Therapeutic Modality for Cushing's Disease
    Ian Lewis, HERBERT A. SCHMID, Rainer Kneuer, Daniël Hoyer, Antonio P. Silva, Gisbert Weckbecker, Christian Bruns, Janos Pless · 2014 · CHIMIA International Journal for Chemistry
20. Endocrinology research—reflecting on the past decade and looking to the next
    Kevan C. Herold, Joseph A. Majzoub, Shlomo K. Melmed, Merri Pendergrass, Martin Jean Schlumberger · 2015 · Nature Reviews Endocrinology
21. Cushing’s disease: current trends in treatment
    Agata Juszczak, Ashley Barry Grossman · 2013 · Clinical Practice
22. Nuevas perspectivas en el tratamiento farmacológico de la enfermedad de Cushing
    María José Barahona, Carlos del Pozo Picó · 2012 · Endocrinología y Nutrición
23. Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors
    Francesco M. Minuto, Diego Ferone, Mara Boschetti, Manuela Albertelli, Federico Gatto · 2014 · Frontiers in diabetes
24. Pasireotide induced adrenal insufficiency
    Kathryn Weaver, Colleen M. Craig, Tracey McLaughlin · 2016 · Clinical Endocrinology
25. Cushing’s Syndrome
    Agata Juszczak, Damian G. Morris, Ashley Barry Grossman, Lynnette K. Nieman · 2015 · Elsevier eBooks
26. Endocrine and metabolic complications of advanced cancer
    Richella Ryan, Ruth Casey · 2021
27. Current and Emerging Pharmacological Therapies for Cushing's Disease
    Efstathios Divaris, Georgios Kostopoulos, Zoe A. Efstathiadou · 2024 · Current Pharmaceutical Design
28. Prediction of remission and recurrence of Cushing’s disease following transsphenoidal surgery (TSS): a single center, 20-year, retrospective series
    Dana Bar Natan, Merav Serebro, Zvi Ram, Rachel Grossman, Naomi Even-Zohar, Yael Sofer, Iris Yaish, Yona Greenman, Karen Michele Tordjman · 2025 · Endocrine
29. Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing’s disease
    Francesco Ferraù, Francesco Trimarchi, Salvatore Cannavò · 2014 · Endocrine
30. Pasireotide for the treatment of Cushing's disease
    A. Colao, C. Simeoli, M. de Leo, A. Cozzolino, R. Pivonello · 2013 · Expert Opinion on Orphan Drugs
31. La enfermedad de Cushing en 2012
    Gabriel Obiols, Betina Biagetti, Ana Chacón Oreja, Javier Salvador Rodríguez · 2013 · Endocrinología y Nutrición
32. Endocrine Disturbances Affecting Reproduction
    Alice Y. Chang, Richard Joseph Auchus · 2013 · Elsevier eBooks
33. High-throughput Screening for Cushing Disease: Therapeutic Potential of Thiostrepton via Cell Cycle Regulation
    Takuro Hakata, Ichiro Yamauchi, Daisuke Kosugi, Taku Sugawa, Haruka Fujita, Kentaro Okamoto, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Nobuya Inagaki · 2024 · Endocrinology
34. Is the new treatment for Cushing's disease too sweet?
    Ashley Barry Grossman · 2017 · The Lancet Diabetes & Endocrinology
35. Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing’s Disease Patients
    Jerry R. Nedelman, Roland D. Fisch, Ke Hu, Inès Paule, Jocelyn Zhou · 2017 · Clinical Pharmacokinetics
36. Medical treatment of neuroendocrine tumours
    Miklós Tóth · 2013 · Orvosi Hetilap
37. Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors
    Leo J. Hofland, Timon Vandamme, Manuela Albertelli, Diego Ferone · 2015 · Frontiers of hormone research
38. Mid-gut ACTH-secreting neuroendocrine tumor unmasked with 18F-dihydroxyphenylalanine-positron emission tomography
    Julien Ducry, Fulgencio Gómez, John Olivier Prior, Ariane Boubaker, Maurice Matter, Matteo Monti, Pu Yan, Nelly Pitteloud, Luc Portmann · 2015 · Endocrinology Diabetes and Metabolism Case Reports
39. Recent Developments in Drug Therapy for Cushing’s Disease
    Rob van der Pas, Wouter W. de Herder, Leo J. Hofland, Richard Abraham Feelders · 2013 · Drugs
40. Trastornos de la glándula suprarrenal: diagnóstico y tratamiento
    Q. Araya Verónica · 2013 · Revista Médica Clínica Las Condes
41. A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
    J.A. Stockman · 2012 · Yearbook of Pediatrics
42. Update on Hypercortisolism Therapy
    Giorgio Arnaldi, Laura Trementino · 2016 · Frontiers of hormone research
43. Therapeutic innovations in endocrine diseases – Part 1: New medical treatments for chronic excess of endogenous cortisol (Cushing's syndrome)
    XAVIER Y. BERTAGNA · 2016 · La Presse Médicale
44. Antiproliferative Effect of Somatostatin Analogs – Data Analyses and Clinical Applications in the Context of the CLARINET Study
    Beatrix Bencsiková · 2016 · Klinicka onkologie
45. Loss of Efficacy of Pasireotide after its Re-Administration: is There a Reason Why?
    Stylianos Mandanas, Lemonia Mathiopoulou, Maria Boudina, Alexandra Chrisoulidou, Kalliopi Pazaitou‐Panayiotou · 2016 · Rare Tumors
46. [Primary epididymal tumors].
    B Pan, Yong Jin Song, X Kong, Z Xue, Yuelin Guo · 1998 · PubMed
47. Endocrine Disturbances Affecting Reproduction
    Alice Y. Chang, Richard Joseph Auchus · 2019 · Elsevier eBooks
48. Cushing Syndrome: Presentation, Diagnosis, and Treatment, Including Subclinical Cushing Syndrome
    Vladimir Kostadinov Neychev · 2016 · Springer eBooks
49. ACTH-Secreting Pituitary Tumors
    Rosario Pivonello, Maria Cristina De Martino, Davide Iacuaniello, Chiara Simeoli, Annamaria Colao · 2014 · Elsevier eBooks
50. Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
    Hamidi, Oksana, St-Jean, Matthieu, Lacroix, André, Bancos, Irina · 2026 · The Journal of Clinical Endocrinology & Metabolism
51. Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study
    Susan Leanne Samson, Ulla Feldt‐Rasmussen, Shao-Ling Zhang, Yerong Yu, Przemysław Witek, Pramila Kalra, Marek Bolanowski · 2024 · Future Rare Diseases
52. Emerging and Established Adverse Events of Pasireotide: A Twelve-Year Pharmacovigilance Study
    Cong Zou, Xing Wang, Ruizhen Huang, Honglin Hu · 2025 · Endocrine Practice
53. Advances in the medical management of hypercortisolism: current strategies, monitoring, and emerging therapies
    Jorge Esteban Mosquera, Leili Rahimi, Oksana Hamidi · 2025 · Current Opinion in Endocrinology Diabetes and Obesity
54. Real-world drug safety study of somatostatin analogs based on the food and drug administration adverse event reporting system database.
    Wangyu Ye, Zhen Liu · 2025 · European Journal of Pharmacology
55. Distinct Amygdala Neuronal Populations Control Opioid Use and Withdrawal in Mice
    Lucas Silva Tortorelli, Htoo Zarni Oo, Suyun Hahn, Yocasta Álvarez-Bagnarol, Yarimar Carrasquillo, Leandro Franco Vendruscolo · 2025 · Biological Psychiatry
56. Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5
    Yang Li, Zhongliang Xing, Wen Hu, Kai Wu, H. Eric Xu, Lihua Zhao · 2025 · Proceedings of the National Academy of Sciences
57. Early hypocortisolism with persistent remission following osilodrostat in a patient with long-standing Cushing disease
    Liat Sasson, Ilan Shimon · 2026 · JCEM Case Reports
58. The effect of pasireotide on intestinal anastomotic healing with and without whole-body irradiation in a rat model
    Gabriel J. Seifert, Gunnar Leithold, Birte Kulemann, Philipp Anton Holzner, Torben Glatz, Jens Hoeppner, Simon Kirste, Goran Marjanović, Claudia Laessle · 2018 · International Journal of Colorectal Disease
59. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations
    Erika Peverelli, Donatella Treppiedi, Giovanna Mantovani · 2022 · Endocrine Oncology
60. Bone mineral density in patients with Cushing’s syndrome
    Aysun Seker, Dilek Gogaş Yavuz · 2024 · Marmara medical journal
61. Ceritinib inhibits growth and ACTH production of PitNETs: Insights from patient-derived organoids
    Haoying Yu, Tingcheng Zhang, Jiaqian Chen, Xueying Li, Huarong Zhang, Rongrong Guo, Chengdong Wu, Li Zhang, Jun Fan, Chaohu Wang et al. · 2025 · Pharmacological Research
62. The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis
    Gianmaria Salvio, Alessandro Ciarloni, Nairus Aboud, Nicola Ambo, Monia Bordoni, Beatrice Lucchetti, Marianna Martino, Michele Perrone, Matteo Gasparroni, Giancarlo Balercia et al. · 2025 · The Journal of Clinical Endocrinology & Metabolism
63. The Management of Neuro-Endocrine Neoplasms
    Amit Akirov, Lama Ghassan Amer, Jessica Chbat, Shereen Ezzat · 2020 · Springer eBooks
64. Maladie de Cushing à imagerie négative chez l’adulte
    Mélanie Philippon, F. Castinettia, Thierry Christian Brue · 2013 · Annales d Endocrinologie
65. Acromegaly: Beyond surgery
    Ashley Barry Grossman, G Thanabalasingham · 2013 · Indian Journal of Endocrinology and Metabolism
66. Medicamental treatment of Itsenko-Cushing’s disease. The current state-of-the art
    Galina Afanas'evna Mel'nichenko, Vera Popovich, Lyudmila Y Rozhinskaya, Zhanna E. Belaya · 2014 · Problems of Endocrinology
67. Cushing’s Disease, Refining the Definition of Remission and Recurrence
    Jeremy N. Ciporen, Justin Schultz Cetas, Shirley McCartney, Maria Fleseriu · 2016 · Springer eBooks
68. Multidisciplinary approach in the diagnosis and therapy of patients with endocrine tumors
    Juan José Díez, Enrique Grande, Teresa Alonso, Pedro Iglesias · 2015 · Medicina Clínica (English Edition)
69. Hormone Excess Syndromes of the Hypothalamic-Pituitary Axis
    Nidhi Agrawal, Hyon Hee Kim, Kyla E. Wright, Sonal Mehta · 2020 · Contemporary Endocrinology
70. Evaluation of Sellar Masses
    Todd B. Nippoldt · 2022 · Springer eBooks
71. Non-surgical Interventions for Pituitary Lesions
    Nisha Suda · 2022 · Otolaryngologic Clinics of North America
72. Pituitary
    John A. H. Wass, Katharine R. Owen, Helen E. Turner · 2014 · Oxford University Press eBooks
73. Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy
    Piero Luigi Ruggenenti, Annalisa Perna, Anna Caroli, Norberto Perico, Matias Trillini, Antonio Pisani, Letìzia Spinelli, Giuseppe Remuzzi · 2022 · Medical Research Archives
74. ACTH-dependent Cushing's syndrome
    Stuti Fernandes, Elena V Varlamov, Maria Fleseriu · 2023 · Elsevier eBooks
75. Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing’s Disease
    Andreea Liliana Serban, Benedetta Zampetti, Andrea Saladino, Vittoria Favero, Iacopo Chiodini, Renato Cesare Cozzi · 2023 · Endocrine Metabolic & Immune Disorders - Drug Targets
76. Forced randomization: the what, why, and how
    Kerstine Carter, Olga M. Kuznetsova, Volodymyr Anisimov, Johannes Krisam, Colin Scherer, Yevgen V. Ryeznik, Oleksandr Sverdlov · 2024 · BMC Medical Research Methodology
77. Pasireotide-Induced Hyperglycemia
    Nitya Kumar · 2017 · MOJ Clinical & Medical Case Reports
78. Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?
    Mimi Wong, Usman Hammawa Malabu, Ipeson Korah, YongMong Tan · 2021 · Endocrinology Diabetes and Metabolism Case Reports
79. Multimodal therapy in aggressive pituitary tumors
    Pedro Iglesias, Rosa Magallón, Mercedes Mitjavila, Víctor Rodríguez Berrocal, Héctor Gerardo Pian, Juan José Díez · 2020 · Endocrinología Diabetes y Nutrición (English ed )
80. Improving outcome in Cushing's syndrome
    Martín Reincke · 2015 · European Journal of Endocrinology
81. Medical Therapy of Hypercortisolism
    Richard Abraham Feelders · 2018 · Elsevier eBooks
82. New Trends in Treating Cushing’s Disease
    Odysseas Violetis, Krystallenia Alexandraki · 2024 · touchREVIEWS in Endocrinology
83. Medical management of Cushing's disease
    Alan Kelsall, John D C Newell-Price · 2021 · Elsevier eBooks
84. Modern principles of the diagnosis and conservative treatment of Cushing disease
    A. Abdali, L. Astafeva, P. Kalinin, Y. Trunin, I. Chernov, G. E. Сhmutin, Abdali Badshahzar, G. Sherzad, Simfukwe Keith · 2020 · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery)
85. Efficacious Primary Pasireotide Therapy in a Case of a Large Invasive Adrenocorticotropin-secreting Pituitary Tumor
    Yuko Tamaki, Junko Nakaue, Fumihiko Nishimura, Yutaka Takahashi · 2023 · JCEM Case Reports
86. Medical Therapies of Cushing’s Disease–Part 2
    Yair Schwarz, Elisabeth Nowak, Reut Halperin, Shruti Shah, Nidhi Agrawal, Richard Abraham Feelders · 2025 · Endocrinology and Metabolism Clinics of North America
87. Medical Therapies of Cushing’s Disease–Part 1
    Yair Schwarz, Elisabeth Nowak, Reut Halperin, Shruti Shah, Nidhi Agrawal, Richard Abraham Feelders · 2025 · Endocrinology and Metabolism Clinics of North America
88. Out of the Box Diagnosis
    Krista Riggs, Lesley Tipton, Samantha Joy · 2026 · Physician Assistant Clinics
89. Neue Arzneimittel 2012
    Uwe Fricke, U. Schwabe · 2013 · Springer eBooks
90. Cushing's disease in 2012
    Gabriel Obiols, Betina Biagetti, Ana Chacón Oreja, Javier Salvador Rodríguez · 2014 · Endocrinología y Nutrición (English Edition)
91. Medical management of Cushing’s syndrome
    Farah Hena Morgan, Marc J. Laufgraben · 2013 · Expert Review of Endocrinology & Metabolism
92. New prospects for drug treatment in Cushing disease
    María José Barahona, Carlos del Pozo Picó · 2012 · Endocrinología y Nutrición (English Edition)
93. Recent advancements in the drug treatment of endocrine diseases
    Amir H. Sam, Karim M. Meeran · 2013 · Clinical Medicine
94. Anaphylaxis and anaesthesia - can treating a cough kill?
    H. Crilly, M. Rose · 2014 · Australian Prescriber
95. Pituitary-Directed Drug Therapy for the Treatment of Cushing's Disease
    Michael Crider · 2013 · Journal of Pharmaceutical Sciences & Emerging Drugs
96. Atypical Pituitary Adenomas
    Gabriel Zada, M. Beatriz S. Lopes, Srinivasan Mukundan, Edward R. Laws · 2015 · Springer eBooks
97. Medical Management for Pituitary Adenoma Patients
    Gregory K. Hong · 2017 · Springer eBooks
98. Are Cushing's disease patients curable?
    XAVIER Y. BERTAGNA · 2018 · Annales d Endocrinologie
99. Pituitary Tumors and Craniopharyngiomas
    John H. Suh, Sam T. Chao, Erin Sennett Murphy, Robert John Weil · 2015 · Elsevier eBooks
100. Adenomi ipofisari
     Emmanuel Jouanneau, Gérald Raverot, Jacqueline Trouillas, G. Brassier · 2015 · EMC - Neurologia